The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.2 - 3 µg/ml. Predicted molecular weight: 24 kDa.
Use a concentration of 3.75 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
FunctionMay participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases.
Tissue specificityWidely expressed. Expressed in ovary, testis, prostate, thymus, muscle and heart, but not in small intestine, colon, lymph nodes, or peripherical blood lymphocytes. The protein is not detected in any of the above organs.
DomainThe coiled coil domain is necessary for the homodimerization.
Cellular localizationGolgi apparatus membrane. According to PubMed:10426319, it also exists as a soluble form which has the same biological activities. The existence of such soluble form is however uncertain.
ab115202 at 3.75 ug/ml, staining EBAG9 in Formalin-fixed, Paraffin-embedded Human skeletal muscle by Immunohistochemistry followed by biotinylated secondary antibody, alkaline phosphatase-streptavidin and chromogen.
Western blot - Anti-EBAG9 antibody (ab115202)
All lanes : Anti-EBAG9 antibody - Carboxyterminal end (ab115202) at 0.2 µg/ml
Lane 1 : A431 cell lysate (in RIPA buffer) Lane 2 : A431 cell lysate (in RIPA buffer) with immunizing peptide
Lysates/proteins at 35 µg per lane.
Developed using the ECL technique
Predicted band size : 24 kDa
References for Anti-EBAG9 antibody - Carboxyterminal end (ab115202)
has not yet been referenced specifically in any publications.
Publishing research using ab115202? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"